[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100521765":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":19,"centralContacts":22,"locations":30,"responsibleParty":64,"collaborators":10,"id":66,"slug":67,"hasResults":68,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":10,"eligibilityCriteria":72,"healthyVolunteers":68,"sex":73,"minAge":74,"maxAge":10,"enrollmentInfo":75,"targetDuration":10,"studyType":78,"phases":10,"briefSummary":79,"conditions":80,"keywords":10,"overallStatus":33,"whyStopped":10,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"Bristol-Myers Squibb","INDUSTRY",[8],{"label":9,"type":10,"description":10,"interventionNames":11},"Participants with myelofibrosis receiving fedratinib",null,[12],"Drug: Fedratinib",[14],{"type":15,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"DRUG","Fedratinib","According to the approved label",[9],[20],{"name":5,"affiliation":5,"role":21},"STUDY_DIRECTOR",[23,28],{"name":24,"role":25,"phone":26,"phoneExt":10,"email":27},"BMS Study Connect Contact Center www.BMSStudyConnect.com","CONTACT","855-907-3286","Clinical.Trials@bms.com",{"name":29,"role":25,"phone":10,"phoneExt":10,"email":10},"First line of the email MUST contain NCT # and Site #.",[31,48,55],{"facility":32,"status":33,"city":34,"state":10,"zip":35,"country":36,"countryCode":10,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"Bristol-Myers Squibb YH","RECRUITING","Seoul","06178","South Korea",{"type":38,"coordinates":39},"Point",[40,41],126.9784,37.566,{"lat":41,"lon":40},[44],{"name":45,"role":25,"phone":46,"phoneExt":10,"email":47},"Ji-Hyun Kim","+82-3404-1300","Ji-hyun.kim@bms.com",{"facility":49,"status":50,"city":34,"state":10,"zip":51,"country":36,"countryCode":10,"cosmosGeoPoint":52,"geoPoint":54,"contacts":10},"Local Institution - 0001","TERMINATED","06234",{"type":38,"coordinates":53},[40,41],{"lat":41,"lon":40},{"facility":56,"status":33,"city":34,"state":10,"zip":51,"country":36,"countryCode":10,"cosmosGeoPoint":57,"geoPoint":59,"contacts":60},"Novotech Laboratory Korea Co., Ltd.",{"type":38,"coordinates":58},[40,41],{"lat":41,"lon":40},[61],{"name":62,"role":25,"phone":63,"phoneExt":10,"email":10},"South Korea Generic Country, Site 0002","0000000000",{"type":65,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100521765","a-post-marketing-surveillance-study-to-assess-the-safety-of-fedratinib-in-korean-patients-with-myelofibrosis-100521765",false,"NCT06073847","A Post-Marketing Surveillance Study to Assess the Safety of Fedratinib in Korean Patients With Myelofibrosis","Inrebic® (Fedratinib) Post-Marketing Surveillance in Korean Patients With Myelofibrosis","Inclusion Criteria:\n\n* Participants 19 years of age or older\n* Participants who will receive fedratinib according to the approved label\n* For the first 2 years after marketing authorization, all participants who have received or are receiving fedratinib will also be registered\n* Participants who signed the informed consent form\n\nExclusion Criteria:\n\n* Participants who have been prescribed fedratinib for an indication not approved in Korea\n* Participants who have been prescribed fedratinib at a dose not approved in Korea\n* Participants for whom fedratinib is contraindicated as clarified in Korean prescribing information approved by the Ministry of Food and Drug Safety","ALL","19 Years",{"count":76,"type":77},137,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to assess the real-world safety of fedratinib for the treatment of adult participants with primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), or post essential thrombocythemia myelofibrosis (post-ET MF) who were previously treated with ruxolitinib. Participants will represent the overall patient population with PMF, post-PV MF or post-ET MF who lost adequate response to and\u002For are intolerant to ruxolitinib. Inadequate response definitions will follow Ministry of Food and Drug Safety-approved label and reimbursement criteria of the Health Insurance Review \\& Assessment Service.",[81,82,83],"Primary Myelofibrosis","Post-polycythemia Vera Myelofibrosis","Post-essential Thrombocythemia Myelofibrosis","2024-11-05",{"date":86,"type":87},"2024-11-06","ACTUAL",{"date":89,"type":87},"2023-06-13",{"date":91,"type":77},"2027-12-20",{"name":5,"class":6},3]